TWI342212B - Liquid pharmaceutical formulations of palonosetron - Google Patents
Liquid pharmaceutical formulations of palonosetron Download PDFInfo
- Publication number
- TWI342212B TWI342212B TW093101810A TW93101810A TWI342212B TW I342212 B TWI342212 B TW I342212B TW 093101810 A TW093101810 A TW 093101810A TW 93101810 A TW93101810 A TW 93101810A TW I342212 B TWI342212 B TW I342212B
- Authority
- TW
- Taiwan
- Prior art keywords
- solution
- rti
- palonosetron
- pharmaceutically acceptable
- patent application
- Prior art date
Links
- 229960002131 palonosetron Drugs 0.000 title claims description 37
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 title claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 title description 5
- 239000007788 liquid Substances 0.000 title description 4
- 206010047700 Vomiting Diseases 0.000 claims abstract description 19
- 229960003359 palonosetron hydrochloride Drugs 0.000 claims abstract description 10
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 56
- 150000003839 salts Chemical class 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 18
- 230000008673 vomiting Effects 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 13
- 239000007979 citrate buffer Substances 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000012929 tonicity agent Substances 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000008155 medical solution Substances 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 abstract description 2
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 35
- 238000009472 formulation Methods 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- -1 i-lithic acid Chemical compound 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 229940090044 injection Drugs 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 5
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- JSWZEAMFRNKZNL-UHFFFAOYSA-N alosetron Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C JSWZEAMFRNKZNL-UHFFFAOYSA-N 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960004106 citric acid Drugs 0.000 description 4
- 229960003727 granisetron Drugs 0.000 description 4
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229960003688 tropisetron Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229960003550 alosetron Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 229940093181 glucose injection Drugs 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229960003413 dolasetron Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MFWNKCLOYSRHCJ-AGUYFDCRSA-N 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide Chemical compound C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-AGUYFDCRSA-N 0.000 description 1
- ZNRGQMMCGHDTEI-FUNVUKJBSA-N 1H-indole-3-carboxylic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical compound C1=CC=C2C(C(=O)OC3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-FUNVUKJBSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- JJIKLKIMWYLYRW-UHFFFAOYSA-N 4-methylbicyclo[2.2.2]oct-2-ene Chemical compound C1CC2CCC1(C)C=C2 JJIKLKIMWYLYRW-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 101100005297 Mus musculus Cat gene Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940059707 anzemet Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- QTFFGPOXNNGTGZ-LIFGOUTFSA-N chembl2368924 Chemical compound O.CS(O)(=O)=O.C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 QTFFGPOXNNGTGZ-LIFGOUTFSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940060963 lotronex Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960003674 tropisetron hydrochloride Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000008918 voyeurism Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940072018 zofran Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
- B65B55/02—Sterilising, e.g. of complete packages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mechanical Engineering (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
1342212 玫、發明說明: 【發明所屬之技術領域】 …本發明乃有關含帕洛諾司璦(叫_如叫之具保存 ,<'&體配方’此配方特別可用於製備注射用藥劑及 口服藥劑。 【先前技術】 嘔吐為胞毒治療、輕射治療、與手術後狀況破壞性極 j的後果,對於接受料治療的人之生活品f造成很大的 =曰近年來,業界已開發被稱為5_ht^5-經色胺)受體抬 抗劑的一組藥物,其係利用枯抗與5η 丁3受體相關的大腦 功能而治療該等嘔吐,參見〜…一。“· "少办〇叮,〇^⑽The Lancet Sep 23, 1 989 及 其中引用的文獻。此組藥物包括昂丹司瓊(。ndansetron)、 格蘭司填(granisetron)、阿洛司填(alosetron)、托烧司瓊 (tropisetron)、與多拉司瓊(d〇lasetr〇n)。彼等 5 HT3 拮抗劑 常於剛要開始化學治療或轄射治療不久前進行靜脈内投 與,於化學治療或輻射治療週期内,可投與一次以上。此 外,彼等藥物亦常呈錠劑或口服液劑形式供應,以補充靜 脈内杈與,或於病患自行實施化療療程時使藥物之居家使 用簡易化。 由方、些化療劑即使僅投與一次,也會引發長達數天 的嘔吐,因此一般希望在嘔吐現象實質上消退之前,每天 投與止嘔劑例如5_HT3拮抗劑。然而,這組5_HT3拮抗劑 尚未被證明格外有助於符合此項需求,因為目前上市的 92538 5 1342212 5-ΗΤ3受體拮抗劑在慢性噁心與嘔吐之調控上未若其對於 急性嘔吐之調控有效,參見Sabra,K. C/2〇/ce 〇/ α Receptor Antagonist for the Hospital Formulary. EHP, Oct. 1 996 ; 2 (suppl 1): s 1 9-24。
近來,已進行有關帕洛諾司瓊(美國專利案5,202,333 中記述的一種新穎的5-HT3受體拮抗劑)之臨床研究。彼等 研究證實,此藥物比多數現有的5-HT3受體拮抗劑更具效 力、令人驚奇地具有大約40小時之半衰期、及可用於減少 由化療劑引發的延緩發作型噁心作嘔。然而,典型地,由 於保存穩定性的問題,將帕洛諾司瓊調配為液體配方並不 容易。美國專利案5,202,333於實例13中揭示含有下列組 成份之帕洛諾司瓊靜脈内配方: 組成份 毫克 帕洛諾司填HC1 10至100毫克 葡萄糖一水合物 適量使等張 檸檬酸一水合物 1.05毫克 氫氧化鈉 0.18毫克 WFJ 至1.0毫升 此配方pH為3.7,其保存穩定性小於多個國家衛生當 局要求之1至2年期限。 昂丹司壤(ondansetron)、其用途、及以其製造之醫藥 品揭示於美國專利案 4,695,578、4,753,789、4,929,632、 5,240,954、5,3 44,65 8、5,578,62 8、5,578,632、5,922,749、 5,622,720、5,955,488、與 6,603,802 中。商業上,昂丹司 6 92538 填係由GlaxoSmithKline公司以Zofran®出售,並標明為用 ’ 於防止手術後噁心與嘔吐(PONV)、癌症化療引起的噁心與 .. °區吐(CINV)、及轄射治療引起的惡心與〇區吐(rinv),可用 形式為注射劑、鍵劑與溶液、及Zofran ODT®(昂丹司填) Orally Disintegrating Tablets( 口服崩解錠劑)。 格蘭司瓊(granisetron)、其用途、及以其製造之醫藥品 揭示於美國專利案 4,886,808、4,937,247、5,034,398 與 6,294,548中。商業上,格蘭司瓊係由R0che Laboratories · 公司以Kytril®出售’標明為用於防止與化學治療或輻射治 療相關的噁心與嘔吐,以錠劑、口服液、及注射劑等形式 提供。 阿洛司瓊(alosetron)、其用途、及以其製造之醫藥品一 揭示於美國專利案5,360,800與6,284,770中。商業上,阿 洛司瓊係由GlaxoSmithKline公司以Lotronex®出售。 市售可得的托烧司瓊(tropisetron)為Navoban® (Novartis) CAS-89565-68-4 (托烷司瓊鹽酸);CAS-1 05 826 · -92-4(托烷司瓊)’標明為用於防止p〇Nv與CINV。 多拉司瓊(dolasetron)、其用途、及以其製造之醫藥品 揭示於美國專利案5,011,846、與4,906,755中。商業上, 多拉司壤係由Aventis Pharmaceuticals公司以Anzemet®出 售,標明為用於防止PONV與CINV,以錠劑或靜脈内溶 液等形式提供。 因此’業界需要穩定性增加,因而保存期加長之帕洛 諾司環配方。亦需要對於有助於製造具有此增加穩定性的 7 92538 1342212 配方之適當濃度範圍的5-HT3受體拮抗劑以及其醫藥上可 接受之載劑。 ' 本發明之目的在於提供用於防止及/或減少嘔吐之具 有增加的醫藥穩定性之帕洛諾司瓊鹽酸鹽配方。 八 本發明之另一目的在於提供使含帕洛諾司瓊鹽酸鹽之 配方穩定之可接受範圍之諸濃度。 本發明之進一步目的在於提供容許長期貯存之帕洛諾 jjp 司禮配方。 本發明之目的也在於提供容許終期滅菌(terminai sterilization)之帕洛諾司瓊配方。 【發明内容】 、 發明人已獲得支持使用帕洛諾司瓊治療及防止嘔吐之 .令人&奇地有效及多方面適用的配方之一系列發現。彼等 配方於室溫時具有1 8個月以上之保存穩定性,因此可以不 必冷藏貯存,及可使用非無菌性、終期滅菌程序進行製造。 % 發明人一方面發現,包含活性成分帕洛諾司瓊之配方 於一些情況下,只需要其他先前已知用於治療嘔吐的化合 物之1/1 0量,此等配方出乎預料地容許使用遠低於—般預 期之帕洛諾司瓊濃度。因此,於一具體實例中,本發明提 供用於防止或減少嘔吐之醫藥上穩定之溶液’其包括4約 〇.〇1毫克/毫升至約5毫克/毫升帕洛諾司瓊或其醫藥上可 接受之鹽;及b)醫藥上可接受之載劑。 發明人進一步發現’藉由調整該配方之pH及/或賦形 劑濃度’彳以增加怕洛諾司瓊配方之穩定性。因此,於另 8 92538 1342212 —具體實例中,本發明提供用於防止或減少嘔吐之醫藥上 穩定之溶液,其包括a)帕洛諾司瓊或其醫藥上可接受之 鹽;及b)醫藥上可接受之載劑’ pH為約4 〇至約6川。於 另一具體實例中,本發明提供用於防止或減少嘔吐之醫藥 上穩定之溶液,其包括約0.01至約5 〇毫克/毫升帕洛諾司 瓊或其醫藥上可接受之鹽;約10至約1〇〇毫莫耳檸檬酸: 緩衝劑;及約〇.〇〇5至約u毫克/毫升EDTA。 發明人進-步發;見,添加甘露糖醇及螯合劑可增加帕 洛諾司壤配方之穩定性。因& ’於又另—具體實例中,本 發明提供用於防止或減少嘔吐之醫藥上穩定之溶液其包 括a)帕洛諾司瓊或其醫藥上可接受之鹽及b)醫藥上可接= ,載劑…醫藥上可接受之载劑包含螯合劑與甘露糖又 [發明之詳細說明] J、肌」思指 η叫〜r双,谷态,亦 可使用密封之其他適當之基本容器’例如,惟不限於,預 充注射器。小瓶亦意指僅使用一次之含藥物之密封容器, 包括會破與不會破的玻璃瓶、會破的塑料瓶、小型螺旋蓋 罐、及僅能容納一個單位劑量帕洛諾司瓊(典型地約5 之其他種類容器。 勹-® 兒明書中,「包括」或其各種變化語態瞭解為音味 ,含所敘述之元件、整體或步驟、或元件、整體或步:之 、且群’惟不排除任何其他元件、整體或步驟、丨元件、整 92538 9 1342212 體或步驟之組群。 「帕洛諾司瓊」意指(3aS)_2,3,3a,4,5,6_六氫_2·[(s)_l_ 氮鍊雙環[2.2·2]辛-3-基]2,3,3a,4,5,6-六氫-l-酮基-l//-笨并 [c?e]異喹啉’較佳為單鹽酸鹽。帕洛諾司瓊單鹽酸鹽可以 下述化學結構式表示:
、 濃度―當本文提及帕洛諾司瓊濃度時,此濃度係以其 .游離鹼之重1測定。所有其他組成份的濃度係以添加於溶 液中的組成份之重量計之。 ^ 「醫藥上可接受」意指用於製備醫藥組成物且通常為 _ 安全、不具毒性及不會於生物學上或者其他方面不受歡 迎,且於獸醫用途以及人類醫藥用途上可接受者。 一 「醫藥上可接受之鹽」意指如上文界定之醫藥上可接 又之鹽類,其具有所需之藥理活性。該等鹽包含與無機酸 例如鹽酸、氫溴酸、硫酸、硝酸、磷酸等;或與有機酸例 虫乙酸、丙酸、己酸、庚酸、環戊烷丙酸、乙醇酸、丙酮 飞、乳酸、丙二酸、琥珀酸、蘋果酸、馬來酸、富馬酸、 i石酸、榉棣酸、苯曱酸、鄰(4_羥基苯曱醯基)笨曱酸、 才土酉文、杏仁g义、甲石黃酸、乙石黃酸、〗,2 -乙二石黃酸、2 _經 92538 10 1342212 基乙磺酸、笨磺酸、對氣笨磺酸、2_萘磺酸、對曱苯磺酸、 樟腦磺酸、4-甲基雙環[2.2.2]辛-2-烯·1·羧酸、葡庚糖酸、 4,4’-伸甲基雙(3-羥基-2-烯-1-羧酸)、3_笨基丙酸、三甲篡 乙酸、第二丁基乙酸、月桂基硫酸、葡萄糖酸、麩胺酸、 羥基萘甲酸、柳酸、硬脂酸、黏康酸(muc〇nic acid)等形 成之酸加成鹽。 此外’當存在的酸性質子能與無機或有機鹼反應時, 亦可形成醫藥上可接受之鹽。可接受之無機鹼包含氫氧化鲁 鈉、碳酸鈉、氫氧化鉀、氫氧化鋁與氫氧化鈣。可接受之 有機鹼包含乙醇胺、二乙醇胺、三乙醇胺、胺基丁三醇、 N-甲基葡萄糖胺等。 【實施方式】 _ 討論 帕洛諾司瓊於一些情況下只需要其他先前已知用於治 療°區吐的化合物之約丨/丨〇量之事實出乎預料地容許使用 遠低於一般預期之帕洛諾司瓊濃度。因此,於一具體實例_ 中,本發明提供用於防止或減少嘔吐之醫藥上穩定之溶 液’其包括a)約0.01毫克/毫升至約5毫克/毫升帕洛諾司 瓊或其醫藥上可接受之鹽;及b)醫藥上可接受之載劑。同 . 樣地’於另一具體實例中’本發明提供調配帕洛諾司瓊之 -醬藥上穩定的溶液之方法,該方法包括摻合约0.01毫克/ 毫升至約5毫克/毫升帕洛諾司瓊或其醫藥上可接受之 鹽;及醫藥上可接受之載劑。於替代具體實例中,該配方 包含濃度為约0,02毫克/毫升至約1.0毫克/毫升,約0.03 11 92538 1342212 ::::升至約。‘2毫克/毫升,最適當為約 之帕洛諾司瓊或其醫藥上可接受之鹽。 克毫升 相關於靜脈内帕洛諾司壤之較低劑量之 於很短、分離期間内以單 t ” ° -般為約ίο至…, 技與之能力。此期間 至3“一 0至約40秒,最佳為約10 5毫升特定具體實財,帕洛諾司錢填充於包含 洛諾司璦)之小瓶令。 毫克/宅升之約心毫克帕 声,進—步發現藉由調整配方之PH及/或賦形劑濃 -曰加帕洛諾司瓊配方之穩定性。因此,於另 體實例中,本發明提供用於 ' 用於防止或減少嘔吐之醫藥上穩定 之洛液’其包括a)帕洛諾司瓊或其醫藥上可接受之 b)醫藥上可接受之載劑,pH為約4〇至約6〇。同樣地, 於^ 一具趙實例中,本發明提供調配帕洛諾司遭之醫藥上 二疋的冷液之方法’ 6亥方法包括摻合a)帕洛諾司壤咬其醫 藥上可接受之鹽…)醫藥上可接受之載劑,沖為約、“ 至約6_0。於替代具體實例中,pH為約45至約55,最適 當為約5.0。對於熟習此項技藝人士而言,調整配方阳之 適當溶液有許多實例’兩個例示溶液為氫氧化納與鹽酸溶 ’夜’二者均可用於調整配方之pH。 於另-具體實例中’本發明提供用於防止或減少〇區吐 之醫藥上穩定之溶液,其包括約〇.〇1至約5〇毫克/毫升帕 洛諾司瓊或其醫藥上可接受之鹽與⑴約】〇至約1〇〇毫莫 耳檸檬酸鹽緩衝劑,及/或(ii)約〇.〇〇5至約i 〇毫克/毫升 92538 12 11342212 EDTA。同樣地,於另一具體實例中,本發明提供調配帕洛 諾司瓊之醫藥上穩定的溶液之方法,該方法包括掺合約 0.01至約5.0毫克/毫升帕洛諾司瓊或其醫藥上可接受之鹽 與(i)約10至約100毫莫耳檸樣酸鹽緩衝劑,及/或(ii)約 0.005至約1.0毫克/毫升EDTA。檸檬酸鹽緩衝劑可為摔樣 酸及/或棒樣鹽(例如桿樣酸三納)之形式。於多個具體實 例中’ 一或多個前述組成份之範圍可修飾如下: •該配方可包含濃度為約θ θ2毫克/毫升至約1 〇毫克 /毫升,約0.03毫克/毫升至約0,2毫克/毫升帕洛諾司瓊鹽 酸鹽,最適當為約0.05毫克/毫升之帕洛諾司瓊或其醫^ 上可接受之鹽》 u •該配方可包含濃度為約10至約40毫莫耳,或約J 5 至30毫莫耳之檸檬酸鹽緩衝劑, .該配方可包含濃度為約〇.〇〇5毫克/毫升至約! 〇毫 克/毫升’或 '約0.3至約〇.7毫克/毫升,及最適當為約/ 毫克/毫升之ED丁A。 ' 發明人進-步發現添加甘露糖醇與髮合劑可增加 7司填配方m因此,w-具體實财,本發明 提供用於防止或減少嘔吐之醫藥上穩定之溶液,其勹 帕洛諾司填或其醫藥上可接受之鹽與》醫藥上可接 :,其中醫藥上可接受之載劑包含聲合劑與甘露糖 樣地’於另-具體實例中,本發明提供調配帕洛 f 穩定溶液之方法’該方法包括摻合a)帕洛 j樂上可接受之鹽與b)醫藥上可接受之載劑,其中[或 92538 13 上可接受之載劑包含整合劑與甘露糖醇。整合劑較佳為 EDTA,於多個具體實例中,螯合劑存在之濃度為從約 立約1.0毫克/毫升或從約0.05毫克/毫升至約1〇毫克/毫 并或從约0.3至約0.7毫克/毫升,或最適當為約〇·5毫克/ 毫升。於多個具體實例令,甘露糖醇存在之濃度為從約1〇 〇 毫克/毫升至約80.0毫克/毫升,從約2〇 〇毫克/毫升至約 6〇.〇毫克/毫升,或最適當為約4〇 〇至約45 〇毫克/毫升。 注射用配方典型地係調配為以水為基本賦形劑之水性 溶液。口服配方與注射用配方的不同一般在於另外存在調 味劑、著色劑、或黏度劑。天然或合成甜味劑包含,例如, 甘露糖醇、山梨糖醇、蔗糖、糖精、阿斯巴甜、阿西沙芬 K (acelsulphame Κ)、或環己基胺磺酸鹽。相對於本發明一 些具體實例中敘述之單純作為張力劑之甘露糖醇濃度々Μ 毫克/¾升,彼等藥劑在作為甜味劑使用時,存在的濃度通 常超過100毫克/毫升或25〇毫克/毫升。 本發明配方特別適於作為注射用及口服液體配方之 用准一般瞭解該等溶液可能具有其他用途。例如,彼等 可作為製備其他醫藥劑量形式之中間體。同樣地,彼等亦 可具有其他投與途徑,包括經鼻内或吸入法。注射用配方 可採取任何途徑,包括經肌内、靜脈内或皮下。 更進一步之具體實例相關於帕洛諾司瓊配方經輕易改 善即可計存或製造相關。特別是,發明人發現本發明配方 各许產品於室溫長期貯存。因此,於另一具體實例中,本 發明提供貯存含有帕洛諾司瓊或其醫藥上可接受之鹽的溶 14 92538 1342212 液之-或多個容器之方法,該方法包括:a)提供可容納該 -或多個容n的空間;b)調整或維持該空間溫度於大於攝 氏約H)、〜戈20度;* c)於該空間貯存該等容器一個月、 3個月、6個用、一年、18個曰 ^ 干個月、或更久(惟最好不超過36 個月),其中⑴該帕洛諾司壤或其醫藥上可接受之鹽存在的
濃度為、约〇.〇1毫克/毫升至約毫克/毫升,(iim^pH 約4.0至約6.0,(iii)該溶液包含約〇〇ι至約5 〇毫克/毫 升帕洛諾司瓊或其醫藥上可接受之鹽,約1〇至約⑽毫莫 耳檸檬酸鹽緩衝劑與約0.005至約! 〇毫克/毫升贿A,、 ㈣該溶液包含整合劑,或(v)該溶液 莫耳檸檬酸鹽緩衝劑^ ^ 1()()爱 前述配方之穩定性導使其本身於製造過程中能良好地 ==程序。因此,於尚另-具體實例中,本發明 有帕洛諾司環或其醫藥上可接受之鹽的溶液之 " 。亥方法包括.a)提供-或多個無菌開口容器 =二毫升小概…)於非無菌環境中,以含帕洛諸司 經密:二:巧器;〇將該等容器密封…對該等 醫藥上可接受之:::订滅函,其中⑴該帕洛諾司填或其 毫去的濃度為約〇·01毫克/毫升至約5.〇 4 = 溶液的PH為約4·°至約",㈤)該溶液包. 之踊约广‘〇毫克/毫升帕洛諾司填或其醫藥上可接受 ^ : _毫莫耳棒樣酸鹽緩衝劑與約〇〇〇5至 溶二克/毫升EDTA,㈣該溶液包含螯合劑,或⑺該 G 3 ’力1 0至約I 00毫莫耳檸檬酸鹽緩衝劑。 92538 15 I342212 [實例]
實例1 :穩定pH 進行研究,測定80°C,ρΗ2·0、5_0、7.4、與10.0時 之穩定性’以決定pH對於含帕洛諾司禮鹽酸鹽的配方之 影響。結果顯示’帕洛諾司瓊鹽酸鹽於pH 5 .〇時最穩定。 宜例2 :穩定濃度窥圍 使用實驗設計軟體進行配方最適化研究。分析二十四 批藥物產品,以調查帕洛諾司瓊鹽酸鹽(〇. 〇 5毫克/毫升至 5.0毫克/ ¾升)、摔樣酸鹽緩衝劑(〇至8〇mjyj)與ed T A (0 至〇· 1 〇%)之適當濃度範圍。根據最適配方選定edta與檸 檬酸鹽緩衝劑之含量,顯示於pH 5 〇時,需以〇 〇5% EDTA 及20 mM檸檬酸鹽緩衝劑進行調配。此研究結果指出,帕 洛諾司瓊/辰度亦為化學穩定性之關鍵因素,於最低帕洛諾 司瓊濃度時觀察到最大之穩定性。 實例3 :張:h彳丨 ^在含a)氣化鈉或者b)甘露糖醇下,製備於檸檬酸鹽緩 衝液中之帕洛諾司瓊鹽酸鹽配方。含甘露糖醇之帕洛諾司 瓊鹽酸鹽®己方顯現較優越之穩定性。發現等張溶液所需甘 露糖醇之最適含量為4.15%。 而 下文為作為靜脈内配方、或藥物的其也液體配 合帕洛諾司瓊之代表性醫藥配方。 92538 16 1342212 組成份 毫克/毫升 帕洛諾司瓊鹽酸鹽 0.05 甘露糖醇 41.5 EDTA 0.5 檸檬酸三鈉 Γ— - · 3.7 檸檬酸 1.56 WFJ 1.0 氫氧化納 >谷液及/或鹽酸溶液 pH 5.0± 0.5
f例5 :配方IT 下文為作為口服配方、或藥物的其他液體配方用之含 帕洛諾司瓊之代表性醫藥配方。 組成份 ] 毫克/毫升 帕洛諾司瓊鹽酸鹽 0.05 甘露糖醇 150 EDTA 0.5 檸檬酸三鈉 3.7 檸檬酸 1.56 WFJ 1.0 氫氧化鈉溶液及/或鹽酸溶液 pH 5.0± 0.5 調味劑 適量
實例6 :不含认窠来松(dexamethasone)的帕洛諾司瑄之穩 定性 於5 %葡萄糖注射液、0 · 9 %氣化鈉注射液、5 %葡萄糖 之0.45%氣化鈉注射液、及5%葡萄糖之乳酸化林格氏注射 17 92538 1342212 ‘液中,針對濃度5微克/毫升與3 〇微克/毫升研究帕洛諾司 .瓊HC1之物理與化學穩定性。於4。(:黑暗處14天及於23 °C螢光下48小時,評估該等摻合物。 於注射液之聚乙烯氣(PVC)袋中,製備濃度5與3〇微 克/毫升之帕洛諾司瓊HC1測試試樣。於開始時,及貯存於 4 C下經1、3 ' 5、7、與M天後及貯存於下經1、*、 24、與48小時後,對試樣之物理與化學穩定性進行評估。 II 4勿理穩定性係使用正常室内光線中之視覺觀察及使用高強 度單向光束予以評估。此外,並以電子方式測定混濁度與 顆粒έ置。藥物之化學穩定性係使用指示穩定性之高效能 液態色層(HPLC)分析技術予以評估。 — 整個研究中,所有試樣均具物理穩定性。溶液保持澄 • β ’微粒負荷及混濁量(haze level)幾無或未見變化。此外, 整個研究期間内,兩個溫度下,任何試樣幾無或未發生帕 洛諾司瓊HC1之喪失。 ^ 含地_塞米松的帕洛諾司瑣之穩定性 研究0.25毫克帕洛諾司瓊HC1於聚乙烯氯(PVC)小袋 中摻合於5%葡萄糖注射液或0 · 9%氣化鈉注射液中之1 〇毫 - 克或20毫克地塞米松(為鈉磷酸鹽),及於聚丙烯注射器中 知合於5%葡萄糖注射液或0.9%氣化鈉注射液中之3.3毫 克地塞米松(為鈉磷酸鹽),於4°c黑暗處14天及於23。(:暴 露於正常實驗室螢光48小時之物理及化學穩定性。 於各輸注液之聚乙烯氣(PVC)小袋中,製備含0.2毫克 /毫升以及0.4毫克/毫升地塞米松(為鈉磷酸鹽)之5微克/ 18 92538 1342212 毫升帕洛諾§]王會XJ P ,、 c 1測試試樣。此外’將於各輸注液中之 含0.33毫克/臺, ^ 也塞米松(為鈉填酸鹽)之2 5微克/毫升帕 〆5复C1製備為於20毫升聚丙烯注射器中之1 〇毫升 H奋液。於開始時,及貯存於4。匸下經丨、3、5、7、與 14天後及貯存於21。广丁 a- 、 C下! I、4、24、與48小時後,對試 樣之物理與化學J.J. '2*, > 心性進仃評估。物理穩定性係使用正常 室内光線中之視覺觀察及使用高強度單向光束予以評估。 此外並以電子方式測定混濁度與顆粒含量。藥物之化學 穩定性係使用指示穩定性 r尤冋效旎液態色層(HPLC)分柄 技術予以評估。 立,=研Μ ’所有試樣均具溶液保持澄 ^門L I負何及,昆,蜀篁幾無或未見變化。此外,整個研究 期間内’兩個溫度下’任何試樣幾無或未 HC1與地塞米松之喪失。 备。右司瓊 本發明已參照其較佳且灿杳t 具體貫例予以敘述。針對本發明 之毖化與修飾,熟習此項技蓺 u 顯而易見。 -..技藝人士-本發明前述詳細說明
9253 S 19
Claims (1)
- T342212 ΓΧ^310181〇 100年3月2日修正替換頁' 拾、申請專利範圍: L 一種用於防止或減少嘔吐之 包括: 诸樂上穩疋之溶液,該溶液 _毫克/毫升至〇.2毫克/毫升帕洛諾司違 (paI〇n〇setron)或其醫藥上可接受之魄及 b)PH為4·〇至6·〇之醫藥上可接受之^劑; 其:,該醫藥上可接受之載劑包括髮合劑和張 2.如申請專利範圍第1項之溶液,其中,該張力劑為氣化 鈉或甘露糖醇。 彳々乳化 3 如申請專利範圍第2項之溶液,直中,兮a# 合欣异〒,該甘露糖醇濃度 為約10.0毫克/毫升至約800毫克/毫升。 4.如申請專利範圍第2項之溶液,立φ 田术q疋冷及具尹,該甘露糖醇濃度 為約40.0毫克/毫升至約45.0毫克/毫升。 5‘如申請專利範圍帛i項之溶液,其中,該整合劑為 EDTA。 6. 如申請專利範圍第5項之溶液,其中,該EDTa的濃度 為約0.005毫克/毫升至約1,〇毫克/毫升。 7. 如申請專利範圍第1項之溶液,其中,該醫藥上可接受 之載劑進一步包括約10至約100毫莫耳之檸檬酸鹽= 衝劑。 8. 如申請專利範圍第!項之溶液,其中,該pH為約4 5至 約 5.5 。 ^ 9.如申請專利範圍第丨項之溶液,其適用於靜脈内投與 10‘如申請專利範圍第1項之溶液,其適用於經口投與 (修正本)9253 8 1 第〇93101810號專利申請案 100年3月2日修正替換頁 1 lb申請專利範 其醫藥上可接 12七申請專利範 至約5.0。 圍第1項之溶液,其中,該帕洛諾司瓊或 又之鹽為帕洛諾司瓊鹽酸鹽。 圍第1項之溶液’其中,該pH為約4.0 ’其中,該帕洛諾司瓊或 0·〇5毫克/毫升。 ’其中’該醫藥上可接受 4 0 ^:莫耳擰檬酸鹽缓衝13’如申請專利範圍帛1項之溶液 其醫藥上可接受之鹽漢度為約 4.如申請專利範圍第1項之溶液 之栽劑進一步包括約10至約 劑。 貯2有帕洛諾司壤或其醫藥上可接受之鹽的溶 或夕個容器之方法,該方法包括: a) 提供容納該一或多個容器之空間; b) 調整或維持該空間溫度大於約攝氏1〇度; c) 於該空間貯存該等容器一個月或更久; 其中’(i)該帕洛諾司瓊或直醫藥卜 約omh,立接受之鹽以浪度為 ·03毫克/毫升至約〇2毫克 PH约4笔兄’毫升存在,(Π)該溶液的 PH,力4.0至約6·〇,(in)該溶液 蒼吞/哀此心卞 3 ',勺〇·〇〇5至約1,〇 毫克/毫升EDTA以及㈣該溶液包含甘露 .如申請專利範圍第15項之方法,龙 1 〇至的1 ΛΛ Α β 、中’該溶液包括約 至力100耄莫耳之檸檬酸鹽緩衝劑。 17.-種裝填含有帕洛諾司瓊或其醫 液no ^土 樂上可接党之鹽的溶 喉Ί谷益之方法’該方法包括: a) 提供一或多個無菌開口容器; b) 於非無菌環境中,以含帕洛諾 壤之溶液裝填該等容 (修正本)92538 2 第093101810號專利申請案 100年3月2曰修正替換頁 器; C)將該等經裝填之容器密封;及 d)對該等經密封、裝填之容器進行滅菌;其中’⑴該帕洛諾司瓊或其醫藥上可接受之鹽以濃度為 約〇·〇3毫克/毫升至約〇·2毫克/毫升存在,(ii)該溶液的 pH為約4.0至約6.0,(iii)該溶液包含約〇 005至約1.〇 毫克/毫升EDTA以及(iv)該溶液包含甘露糖醇。 18.如申請專利範圍第17項之方法,其中,該溶液包括約 10至約1 〇〇毫莫耳之擰檬酸鹽缓衝劑。 3 (修正本)92538
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44435103P | 2003-01-30 | 2003-01-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200418517A TW200418517A (en) | 2004-10-01 |
TWI342212B true TWI342212B (en) | 2011-05-21 |
Family
ID=32825409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093101810A TWI342212B (en) | 2003-01-30 | 2004-01-28 | Liquid pharmaceutical formulations of palonosetron |
Country Status (41)
Country | Link |
---|---|
US (9) | US7947724B2 (zh) |
EP (2) | EP2008659A1 (zh) |
JP (2) | JP5461763B2 (zh) |
KR (1) | KR101113084B1 (zh) |
CN (2) | CN102813621A (zh) |
AP (1) | AP2110A (zh) |
AR (1) | AR042977A1 (zh) |
AT (1) | ATE410167T1 (zh) |
AU (1) | AU2004208505C1 (zh) |
BR (1) | BRPI0407121B8 (zh) |
CA (5) | CA2573363A1 (zh) |
CR (1) | CR7921A (zh) |
CY (1) | CY1108660T1 (zh) |
DE (1) | DE602004016967D1 (zh) |
DK (1) | DK1601359T3 (zh) |
EA (1) | EA014066B1 (zh) |
EC (1) | ECSP055938A (zh) |
ES (1) | ES2315635T3 (zh) |
GE (1) | GEP20084445B (zh) |
HK (1) | HK1076401A1 (zh) |
HR (1) | HRP20050676B1 (zh) |
IL (1) | IL169859A (zh) |
IS (1) | IS7984A (zh) |
JO (1) | JO2735B1 (zh) |
MA (1) | MA27710A1 (zh) |
MX (1) | MXPA05008028A (zh) |
MY (1) | MY144036A (zh) |
NO (1) | NO329500B1 (zh) |
NZ (1) | NZ541533A (zh) |
PA (1) | PA8594801A1 (zh) |
PE (1) | PE20050066A1 (zh) |
PL (1) | PL378398A1 (zh) |
PT (1) | PT1601359E (zh) |
RS (1) | RS20050578A (zh) |
SI (1) | SI1601359T1 (zh) |
TN (1) | TNSN05180A1 (zh) |
TW (1) | TWI342212B (zh) |
UA (1) | UA90449C2 (zh) |
UY (1) | UY28175A1 (zh) |
WO (1) | WO2004067005A1 (zh) |
ZA (1) | ZA200506917B (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003302072A1 (en) * | 2002-11-15 | 2004-06-15 | Helsinn Healthcare Sa | Palonosetron for the treatment of chemotherapy-induced emesis |
JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
US8598219B2 (en) | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
MY143789A (en) * | 2003-02-18 | 2011-07-15 | Helsinn Healthcare Sa | Use of palonosetron treating post- operative nausea and vomiting |
CN100336508C (zh) * | 2005-02-23 | 2007-09-12 | 重庆医药工业研究院有限责任公司 | 一种稳定的帕洛诺司琼注射液 |
CN100455286C (zh) * | 2006-11-21 | 2009-01-28 | 深圳海创医药科技发展有限公司 | 帕洛诺司琼注射液及其制备方法 |
US9061076B2 (en) | 2007-05-25 | 2015-06-23 | North Carolina State University | Viral nanoparticle cell-targeted delivery platform |
US20100048607A1 (en) * | 2008-08-25 | 2010-02-25 | Chandrashekhar Kocherlakota | Formulations comprising palonosetron |
WO2010077669A2 (en) | 2008-12-08 | 2010-07-08 | Teva Pharmaceutical Industries Ltd. | Palonosetron formulation |
US20130213393A1 (en) | 2009-12-22 | 2013-08-22 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
EP2499137A1 (en) | 2009-11-13 | 2012-09-19 | Helsinn Healthcare S.A. | Palonosetron metabolites |
ES2623503T3 (es) | 2009-11-18 | 2017-07-11 | Helsinn Healthcare Sa | Composiciones para tratar náuseas y vómitos mediados centralmente |
EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
KR101368587B1 (ko) * | 2010-12-27 | 2014-03-05 | 주식회사 삼양바이오팜 | 오심 또는 구토 방지용 조성물 |
EP2759298B1 (en) | 2011-10-18 | 2018-01-17 | Helsinn Healthcare SA | Therapeutic combinations of netupitant and palonosetron |
CN105934247A (zh) | 2013-12-23 | 2016-09-07 | 株式会社三养生物制药 | 包含帕洛诺司琼的药物组合物 |
CN104784107A (zh) * | 2014-01-17 | 2015-07-22 | 南京瑞尔医药有限公司 | 一种盐酸托烷司琼口服液的制备方法 |
KR20160128573A (ko) * | 2015-04-29 | 2016-11-08 | 주식회사 삼양바이오팜 | 약제학적 패키지 |
LT3435980T (lt) * | 2016-06-06 | 2020-02-25 | Helsinn Healthcare Sa | Fiziologiškai subalansuotos injekcinės fosnetupitanto kompozicijos |
JP6768404B2 (ja) * | 2016-08-12 | 2020-10-14 | 武田テバファーマ株式会社 | パロノセトロン又はその薬学的に許容される塩を含む医薬組成物 |
JP6705348B2 (ja) * | 2016-09-23 | 2020-06-03 | ニプロ株式会社 | 液体製剤、及び、パロノセトロンの安定性を向上する方法 |
JP6642377B2 (ja) * | 2016-10-25 | 2020-02-05 | ニプロ株式会社 | 液体製剤、及び、パロノセトロンの安定性を向上する方法 |
KR101802183B1 (ko) * | 2016-11-16 | 2017-11-28 | 주식회사 유영제약 | 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물 |
EP3672964A4 (en) | 2017-08-21 | 2021-05-26 | Leiutis Pharmaceuticals Pvt. Ltd. | NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY |
HUE062180T2 (hu) * | 2018-01-12 | 2023-09-28 | Orion Corp | Palonosetron szemcsepp a hányinger és a hányás kezelésére vagy megelõzésére |
JP7090845B2 (ja) * | 2018-08-03 | 2022-06-27 | 高田製薬株式会社 | パロノセトロン含有液体組成物 |
JP7438802B2 (ja) * | 2020-03-23 | 2024-02-27 | シオノギファーマ株式会社 | パロノセトロン含有組成物 |
WO2024147073A1 (en) * | 2023-01-03 | 2024-07-11 | Helsinn Healthcare Sa | Liquid oral formulations of netupitant and palonosetron |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS599539B2 (ja) * | 1979-11-13 | 1984-03-03 | 日本化薬株式会社 | ニトログリセリン水溶液及びその製造法 |
US4695578A (en) | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
EP0200444B1 (en) | 1985-04-27 | 1992-11-11 | Beecham Group Plc | Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity |
US4937247A (en) | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
GB8516083D0 (en) | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
US5578628A (en) | 1985-06-25 | 1996-11-26 | Glaxo Group Limited | Medicaments for the treatment of nausea and vomiting |
US5240954A (en) | 1985-06-25 | 1993-08-31 | Glaxo Group Limited | Medicaments |
US4906755A (en) | 1986-11-03 | 1990-03-06 | Merrell Dow Pharmaceuticals Inc. | Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds |
US5360800A (en) | 1987-09-03 | 1994-11-01 | Glaxo Group Limited | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives |
US5011846A (en) | 1988-02-23 | 1991-04-30 | Merrell Dow Pharmaceuticals Inc. | Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof |
US5344658A (en) | 1989-06-28 | 1994-09-06 | Glaxo Group Limited | Process and composition using ondansetron |
GB8914804D0 (en) | 1989-06-28 | 1989-08-16 | Glaxo Group Ltd | Process |
ZA909529B (en) | 1989-11-28 | 1992-08-26 | Syntex Inc | New tricyclic compounds |
WO1992019617A2 (en) | 1991-05-03 | 1992-11-12 | G.D. Searle & Co. | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
US5272137A (en) | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
GB9305593D0 (en) * | 1993-03-18 | 1993-05-05 | Smithkline Beecham Plc | Pharmaceuticals |
US5567818A (en) * | 1994-07-08 | 1996-10-22 | Syntex (U.S.A.) Inc. | Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein |
GB9423588D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
GB9423511D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
JP3845902B2 (ja) * | 1996-07-09 | 2006-11-15 | ソニー株式会社 | 磁気記録再生装置 |
ATA156496A (de) | 1996-09-03 | 1997-10-15 | Nycomed Austria Gmbh | Pharmazeutische zusammensetzung |
GB9625589D0 (en) * | 1996-12-10 | 1997-01-29 | Boots Co Plc | Therapeutic agents |
US20030095926A1 (en) | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
GB9721139D0 (en) | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
US6294548B1 (en) | 1998-05-04 | 2001-09-25 | Hoffmann-La Roche Inc. | Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride |
US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
DE19833119A1 (de) | 1998-07-23 | 2000-01-27 | Roche Diagnostics Gmbh | Spritzfertige Injektionslösungen enthaltend Carvedilol |
CA2340225A1 (en) * | 1998-10-27 | 2000-05-04 | Wesley Wehsin Han | Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap |
US6699852B2 (en) * | 2000-12-20 | 2004-03-02 | Bristol-Myers Squibb Pharma Company | Substituted pyridoindoles as serotonin agonists and antagonists |
WO2002092082A1 (en) | 2001-05-11 | 2002-11-21 | Mitsubishi Pharma Corporation | Stable high-concentration injection containing pyrazolone derivative |
AU2003237657A1 (en) | 2002-05-24 | 2003-12-12 | Epidauros Biotechnologie Ag | Means and methods for improved treatment using "setrones" |
AU2003302072A1 (en) | 2002-11-15 | 2004-06-15 | Helsinn Healthcare Sa | Palonosetron for the treatment of chemotherapy-induced emesis |
EP1581221B1 (en) * | 2002-12-19 | 2011-05-18 | Bristol-Myers Squibb Company | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
DE602004005814T2 (de) | 2003-01-13 | 2008-01-10 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus |
JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
US8598219B2 (en) | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
MY143789A (en) * | 2003-02-18 | 2011-07-15 | Helsinn Healthcare Sa | Use of palonosetron treating post- operative nausea and vomiting |
-
2004
- 2004-01-27 JO JO20042A patent/JO2735B1/en active
- 2004-01-28 TW TW093101810A patent/TWI342212B/zh not_active IP Right Cessation
- 2004-01-29 MY MYPI20040261A patent/MY144036A/en unknown
- 2004-01-29 AR ARP040100279A patent/AR042977A1/es not_active Application Discontinuation
- 2004-01-30 PA PA20048594801A patent/PA8594801A1/es unknown
- 2004-01-30 CA CA002573363A patent/CA2573363A1/en not_active Abandoned
- 2004-01-30 CA CA002573241A patent/CA2573241A1/en not_active Abandoned
- 2004-01-30 CN CN2012102874523A patent/CN102813621A/zh active Pending
- 2004-01-30 MX MXPA05008028A patent/MXPA05008028A/es active IP Right Grant
- 2004-01-30 PT PT04706657T patent/PT1601359E/pt unknown
- 2004-01-30 RS YUP-2005/0578A patent/RS20050578A/sr unknown
- 2004-01-30 CN CNA2004800063221A patent/CN1758911A/zh active Pending
- 2004-01-30 CA CA002573194A patent/CA2573194A1/en not_active Abandoned
- 2004-01-30 PE PE2004000115A patent/PE20050066A1/es not_active Application Discontinuation
- 2004-01-30 PL PL378398A patent/PL378398A1/pl not_active Application Discontinuation
- 2004-01-30 JP JP2006501686A patent/JP5461763B2/ja not_active Expired - Lifetime
- 2004-01-30 UY UY28175A patent/UY28175A1/es not_active IP Right Cessation
- 2004-01-30 DE DE602004016967T patent/DE602004016967D1/de not_active Expired - Lifetime
- 2004-01-30 CA CA002573228A patent/CA2573228A1/en not_active Abandoned
- 2004-01-30 SI SI200430976T patent/SI1601359T1/sl unknown
- 2004-01-30 EA EA200501203A patent/EA014066B1/ru unknown
- 2004-01-30 NZ NZ541533A patent/NZ541533A/en not_active IP Right Cessation
- 2004-01-30 UA UAA200508414A patent/UA90449C2/ru unknown
- 2004-01-30 EP EP08015410A patent/EP2008659A1/en not_active Withdrawn
- 2004-01-30 ES ES04706657T patent/ES2315635T3/es not_active Expired - Lifetime
- 2004-01-30 GE GEAP20048958A patent/GEP20084445B/en unknown
- 2004-01-30 AU AU2004208505A patent/AU2004208505C1/en not_active Expired
- 2004-01-30 KR KR1020057014093A patent/KR101113084B1/ko active IP Right Review Request
- 2004-01-30 WO PCT/EP2004/000888 patent/WO2004067005A1/en active Application Filing
- 2004-01-30 CA CA002514224A patent/CA2514224C/en not_active Expired - Lifetime
- 2004-01-30 BR BRPI0407121A patent/BRPI0407121B8/pt active IP Right Grant
- 2004-01-30 AT AT04706657T patent/ATE410167T1/de active
- 2004-01-30 AP AP2005003382A patent/AP2110A/xx active
- 2004-01-30 EP EP04706657A patent/EP1601359B1/en not_active Revoked
- 2004-01-30 DK DK04706657T patent/DK1601359T3/da active
-
2005
- 2005-07-21 US US11/186,311 patent/US7947724B2/en not_active Expired - Lifetime
- 2005-07-22 CR CR7921A patent/CR7921A/es unknown
- 2005-07-25 IL IL169859A patent/IL169859A/en active IP Right Grant
- 2005-07-27 TN TNP2005000180A patent/TNSN05180A1/en unknown
- 2005-07-27 HR HRP20050676AA patent/HRP20050676B1/hr active IP Right Review Request
- 2005-07-29 EC EC2005005938A patent/ECSP055938A/es unknown
- 2005-08-12 MA MA28440A patent/MA27710A1/fr unknown
- 2005-08-15 IS IS7984A patent/IS7984A/is unknown
- 2005-08-26 NO NO20053987A patent/NO329500B1/no not_active IP Right Cessation
- 2005-08-29 ZA ZA200506917A patent/ZA200506917B/xx unknown
- 2005-12-07 HK HK05111168A patent/HK1076401A1/xx not_active IP Right Cessation
-
2006
- 2006-03-24 US US11/388,270 patent/US7960424B2/en not_active Expired - Lifetime
- 2006-03-24 US US11/388,268 patent/US7947725B2/en active Active
-
2008
- 2008-12-22 CY CY20081101485T patent/CY1108660T1/el unknown
-
2011
- 2011-04-14 US US13/087,012 patent/US8518981B2/en not_active Expired - Lifetime
- 2011-07-28 JP JP2011165212A patent/JP5551658B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-23 US US13/901,288 patent/US8598218B2/en not_active Expired - Lifetime
- 2013-10-14 US US14/052,925 patent/US20140039000A1/en not_active Abandoned
- 2013-11-04 US US14/070,981 patent/US9308266B2/en not_active Expired - Fee Related
-
2015
- 2015-09-16 US US14/855,564 patent/US9457020B2/en not_active Expired - Lifetime
-
2016
- 2016-07-14 US US15/209,995 patent/US20160317440A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI342212B (en) | Liquid pharmaceutical formulations of palonosetron | |
US9457021B1 (en) | Liquid pharmaceutical formulations of palonosetron | |
US20060167072A1 (en) | Liquid pharmaceutical formulations of palonosetron |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |